Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent research reports. Barclays upped their price target on Eli Lilly and from $333.00 to $355.00 and gave the company an "overweight" rating in a research report on Thursday, July 7th. Mizuho increased their price objective on Eli Lilly and from $315.00 to $356.00 in a report on Monday, May 2nd. UBS Group increased their price objective on Eli Lilly and to $335.00 and gave the stock an "outperform" rating in a report on Wednesday, July 27th. StockNews.com cut Eli Lilly and from a "strong-buy" rating to a "buy" rating in a report on Friday, August 5th. Finally, JPMorgan Chase & Co. increased their price objective on Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $317.00.

Eli Lilly and Price Performance

Shares of Eli Lilly and stock opened at $301.17 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $286.16 billion, a PE ratio of 47.99, a price-to-earnings-growth ratio of 2.07 and a beta of 0.35. The business's 50-day moving average price is $315.34 and its 200-day moving average price is $290.26. Eli Lilly and has a 12 month low of $220.20 and a 12 month high of $335.33.

Eli Lilly and (NYSE:LLY - Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). The firm had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. Eli Lilly and's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.87 earnings per share. Sell-side analysts forecast that Eli Lilly and will post 7.96 EPS for the current fiscal year.

Eli Lilly and Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be given a dividend of $0.98 per share. The ex-dividend date is Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.30%. Eli Lilly and's payout ratio is 62.52%.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 89,458 shares of the firm's stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the transaction, the insider now directly owns 103,875,441 shares in the company, valued at approximately $34,574,940,536.85. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of the stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $332.85, for a total value of $29,776,095.30. Following the completion of the sale, the insider now owns 103,875,441 shares in the company, valued at approximately $34,574,940,536.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total value of $313,440.00. Following the completion of the sale, the chief accounting officer now owns 6,274 shares of the company's stock, valued at approximately $1,966,522.56. The disclosure for this sale can be found here. Insiders have sold a total of 1,195,396 shares of company stock worth $380,134,601 in the last ninety days. 0.12% of the stock is owned by insiders.